Top Markets
#1 Black Phoenix Black Phoenix +198.52%
#2 Islamic Coin Islamic Coin +158.00%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +45.63%
#5 BasedHype BasedHype +39.57%
#6 Acurast Acurast +23.87%
#7 Cryptopia Cryptopia +21.79%
#8 Quantum Resistant Ledger Quantum Resistant Ledger +21.41%
#9 Moolah Moolah +17.16%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.57%
Coin of the day
Black Phoenix Black Phoenix
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Imaging Biometrics Ltd. Imaging Biometrics Ltd.

Imaging Biometrics Ltd.

IBAI
Classement en actions #41380
Imaging Biometrics Ltd., founded in 1965 and headquartered in Saint Helier,... Imaging Biometrics Ltd., founded in 1965 and headquartered in Saint Helier, Jersey, specializes in medical imaging diagnostics and clinical patient care. The company extends its services across the United Kingdom, Switzerland, the European Union, and the United States. Its operations are structured into three main segments: a Holding Company, Medical Software, and Oral Gallium Maltolate (GaM). The Medical Software division develops a comprehensive suite of ready-to-use software applications for the healthcare sector. This portfolio includes IB Clinic, which serves as the foundational platform for all IB software; IB Neuro, a specialized platform for MR DSC perfusion processing; and IB Delta Suite, designed to generate Delta T1 maps from routine MR examinations. Further offerings comprise IB DCE and IB Diffusion, both providing in-depth insights into blood flow and water diffusion throughout the body. For non-invasive assessments, the company provides StoneChecker and Liver Surface Nodularity, which are computed tomography (CT) processing tools that assist clinicians in evaluating kidney stones and liver health. Additional software includes IB ASL, used to measure cerebral blood flow for diagnosing conditions like stroke and dementia, and IB Zero G, an innovative technology that eliminates the need for gadolinium contrast agents in standard imaging. The suite also features IB Nimble, facilitating virtual collaboration among healthcare professionals. Beyond software, the company's Oral Gallium Maltolate (GaM) segment is actively pursuing the development of IB003, a gallium maltolate drug candidate currently in Phase 1 clinical trials for treating glioblastoma. Imaging Biometrics Ltd. also offers consulting services. The entity, which was previously known as IQ-AI Limited, is slated to adopt the name Imaging Biometrics Ltd. in May 2025.
Prix de l'action
$0.01088561
Capitalisation boursière
$26.86K
Changement (1 jour)
14.29%
Changement (1 an)
33.61%
Pays
JE
Échange Imaging Biometrics Ltd. (IBAI)

Catégorie

Healthcare
Ratio P/E pour Imaging Biometrics Ltd. (IBAI)
Ratio P/E au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Imaging Biometrics Ltd., le ratio P/E actuel (TTM) est de 0. À la fin de l’année 2026, le P/E de l’entreprise était de 0.
Historique du ratio P/E pour Imaging Biometrics Ltd. de 2026 à 2026
Ratio P/E à la fin de chaque année
Année Ratio P/E Changez
Pas assez de données pour les dates fournies.
Ratio P/E pour des entreprises similaires ou concurrentes
Entreprise P/E Ratio Différence du P/E Ratio Pays
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
 19.55 -
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
 72.09 -
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
 41.76 -
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
 -30.68 -
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
 - -
US
Comment lire un P/E ratio ?

Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.

Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.

Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.